IDH1 and glioblastoma: The results showed that there was no significant difference in the risk score between primary and recurrence GBMs (Fig. 4A), whereas, the score for GBM with IDH mutation and MGMT promoter methylation was significantly lower than that for GBM with wildtype IDH and unmethylated MGMT promoter (Fig. 4B and C).